PARG1 Antikörper (AA 301-400) (Cy7)
Kurzübersicht für PARG1 Antikörper (AA 301-400) (Cy7) (ABIN762407)
Target
Alle PARG1 (ARHGAP29) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 301-400
-
Kreuzreaktivität
- Human
-
Homologie
- Mouse,Rat,Dog,Cow,Pig,Horse,Rabbit
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human PARG1
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- PARG1 (ARHGAP29) (rho GTPase Activating Protein 29 (ARHGAP29))
-
Andere Bezeichnung
- Rho GTPase activating protein 29
-
Hintergrund
-
Synonyms: PARG1, Rho GTPase-activating protein 29, PTPL1-associated RhoGAP protein 1, Rho-type GTPase-activating protein 29, ARHGAP29
Background: GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state. Has strong activity toward RHOA, and weaker activity toward RAC1 and CDC42. May act as a specific effector of RAP2A to regulate Rho. In concert with RASIP1, suppresses RhoA signaling and dampens ROCK and MYH9 activities in endothelial cells and plays an essential role in blood vessel tubulogenesis.
-
Gen-ID
- 9411
-
UniProt
- Q52LW3
Target
-